24 okt: Schering: Undersøgelsesresultat vedr. tidlig MS offentlig...
24 okt: Fabricius og Kastholms møbelklassikere
24-10-2006 11:39:00

Hugin Ad hoc announcement according to § 15 WpHG: Misc. business figure: STRATEC Biomedical Systems AG: STRATEC clearly exceeds earnings for overall previous year after only nine months

Birkenfeld, October 24, 2006

The Board of Management of STRATEC Biomedical Systems AG, which is

listed in the Prime Standard and Gate-M indices, hereby announces the

preliminary, unaudited consolidated figures based on IFRS

(International Financial Reporting Standards) of the STRATEC Group

for the first nine months of the 2006 financial year pursuant to

Section 15 of the German Securities Trading Act (WpHG).

+-------------------------------------------------------------------+

| Key Figures (EUR | 01.01.- | 01.01.- | Change |

| 000s) | 09.30.2006 | 09.30.2005 | |

|---------------------+-----------------+-----------------+---------|

| Sales | 51,933 | 33,945 | + 53.0% |

|---------------------+-----------------+-----------------+---------|

| Gross performance | 51,887 | 35,582 | + 45.8% |

|---------------------+-----------------+-----------------+---------|

| EBITDA | 8,295 | 5,315 | + 56.1% |

|---------------------+-----------------+-----------------+---------|

| EBIT | 7,199 | 4,587 | + 56.9% |

|---------------------+-----------------+-----------------+---------|

| EBT | 7,097 | 4,409 | + 61.0% |

|---------------------+-----------------+-----------------+---------|

| Consolidated net | 5,304 | 2,895 | + 83.2% |

| income | | | |

|---------------------+-----------------+-----------------+---------|

| Earnings per share | 0.48 | 0.29 | + 65.5% |

| (EUR) | | | |

+-------------------------------------------------------------------+

The STRATEC Group had a total of 215 employees as of

September 30, 2006 (previous year: 189).

Information and disclosures concerning this ad-hoc announcement:

Irrespective of possible new levels of sales and earnings correlating

with the market launch of new analyzer system families, the company

assumes that the seasonal fluctuations witnessed in sales and

earnings in the past will be increasingly countered by logistical

measures involving procurement and production.

In the past 2005 financial year, the STRATEC Group had an average of

191 employees and generated sales of Euro 47.3 million, earnings

before tax (EBT) of Euro 6.9 million and consolidated income of Euro

4.4 million, with earnings per share of Euro 0.43 (earnings for

overall previous year).

The extensive interim report will be available on our internet page

as a download from around 3 p.m. on November 8, 2006.

Based on current budgeting, the growth forecast for the company will

be reflected in particular from the second and third quarter of the

2007 financial year onwards.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)

designs and manufactures fully automated systems for its partners in

the fields of clinical diagnostics and biotechnology. These partners

market such systems, in general together with their own reagents, to

laboratories and research institutes around the world. The company

develops its products on the basis of its own patented technologies.

Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded

in the Prime Standard segment of the Frankfurt Stock Exchange, in the

Gate-M trading segment of the Stuttgart Stock Exchange and on other

exchanges.

The STRATEC Group comprises the listed holding company "STRATEC

Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",

"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestrasse 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

E-Mail: ir@stratec-biomedical.de

--- End of Ad-hoc Message ---

WKN: 728900; ISIN: DE0007289001;

Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in

Börse Stuttgart,

Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse

München,

Freiverkehr in Börse Düsseldorf;

Copyright © Hugin ASA . All rights reserved.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
25 mar
GEN
Der er intet mere forfriskende end den intellektuelle udfordring, man føler ved en kvalificeret deba..
18
22 mar
VWS
Selskabet Alpha Wind Energy fra Bjerringbro har sendt en ansøgning til US Interior Department om at ..
16
23 mar
VWS
“Apex Offshore Wind” er et datter-selskab under “Apex Wind Energy Holdings” og dette selskab har A.P..
15
21 mar
OMXC20
Ja alle starter et sted og det er absolut ikke træls at nye investorer spørger om råd. Det er i mine..
14
26 mar
OMXC20
Der er ingen korrektion igang, bare lidt ligegyldig panik fordi Saudi har bombet nogle oprørere i Ye..
12
21 mar
EXQ
Hermed det lovede referat. Der blev ikke sagt SÅ meget nyt, det meste var ting man læse i årsrapport..
12
22 mar
OMXC20
Med det beløb er 10 forskellige nok i overkanten til at starte med. Start evt. med det halve og udby..
11
26 mar
OMXC20
Israelerne er de eneste Vesten kan stole på i Mellemøsten.   Ganske enkelt vore eneste sande alliere..
10
24 mar
I:DAX
Den debat du skal have her er om man skal forholde sig til virkeligheden er i dag eller hvordan den ..
10
23 mar
 
http://npinvestor.dk/nyheder/gr%C3%A6kenland-tsipras-klager-sin-n%C3%B8d-i-brev-til-merkel   Smid de..
10

Carlsberg-konkurrent frygter svækket konkurrence i Grækenland

27-03-2015 16:44:49
Konkurrencen på det græske ølmarked kan blive svækket markant set i lyset af, at de græske konkurrencemyndigheder uden betænkninger har godkendt fusionen mellem..

WDH/dir: Oticon Medical snart klar med første implantat

27-03-2015 14:23:55
William Demant Holdings kirurgiske division, Oticon Medical, fortsætter fremad for fuldt blus. Forretningsbenet har de seneste år hentet enorm vækst, og det spo..

Novo og Genmabs stiger mest blandt europæiske elitepapirer

27-03-2015 10:30:07
Novo Nordisk og Genmab topper fredag formiddag indekset over de største europæiske aktier, Stoxx 600. Med kursstigninger på henholdsvis 9,2 og 6,5 pct. distance..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo-aktionærer har noget at glæde sig til
2
Torm-aktionærer får vredet armen om af kapitalfond - avis
3
Novo: Langsigtet mål kan kun indfris med Tresiba - NY
4
Novo og Genmabs stiger mest blandt europæiske elitepapirer
5
Aktier/åbning: Novo Nordisk tager kursraketten

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. marts 2015 18:18:13
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150325.1 - EUROWEB2 - 2015-03-27 18:18:13 - 2015-03-27 18:18:13 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x